344 related articles for article (PubMed ID: 24369281)
1. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Watanabe R; Okazaki R
Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
[TBL] [Abstract][Full Text] [Related]
2. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Lewiecki EM
IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
[TBL] [Abstract][Full Text] [Related]
3. [Odanacatib (MK-0822)].
Nagase Y; Tanaka S
Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cathepsin K for treatment of osteoporosis.
Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
6. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
7. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
8. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
[TBL] [Abstract][Full Text] [Related]
9. [Cathepsin K antagonists: preclinical and clinical data].
Gamsjäger M; Resch H
Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
11. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
Schultz TC; Valenzano JP; Verzella JL; Umland EM
Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
[TBL] [Abstract][Full Text] [Related]
12. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.
Costa AG; Cusano NE; Silva BC; Cremers S; Bilezikian JP
Nat Rev Rheumatol; 2011 Jun; 7(8):447-56. PubMed ID: 21670768
[TBL] [Abstract][Full Text] [Related]
14. Potential role of odanacatib in the treatment of osteoporosis.
Ng KW
Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
[TBL] [Abstract][Full Text] [Related]
15. Molecular and cellular basis of bone resorption.
Gruber R
Wien Med Wochenschr; 2015 Feb; 165(3-4):48-53. PubMed ID: 25223736
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches to the treatment of osteoporosis.
Appelman-Dijkstra NM; Papapoulos SE
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):843-57. PubMed ID: 25432356
[TBL] [Abstract][Full Text] [Related]
18. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.
Pennypacker BL; Chen CM; Zheng H; Shih MS; Belfast M; Samadfam R; Duong LT
J Bone Miner Res; 2014 Aug; 29(8):1847-58. PubMed ID: 24591096
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.
Brömme D; Panwar P; Turan S
Expert Opin Drug Discov; 2016; 11(5):457-72. PubMed ID: 27001692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]